Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

被引:2
|
作者
Reddy, Nishith R. [1 ,2 ]
Maachi, Hasna [3 ,9 ,10 ,11 ,12 ,13 ]
Xiao, Yini [1 ,2 ,3 ]
Simic, Milos S. [1 ,2 ]
Yu, Wei [1 ,2 ]
Tonai, Yurie [1 ,2 ]
Cabanillas, Daniela A. [1 ,2 ]
Serrano-Wu, Ella [1 ,2 ]
Pauerstein, Philip T. [1 ,4 ]
Tamaki, Whitney [5 ]
Allen, Greg M. [1 ,6 ,7 ,8 ]
Parent, Audrey V. [3 ]
Hebrok, Matthias [3 ,9 ,10 ,11 ,12 ,13 ]
Lim, Wendell A. [1 ,2 ,7 ]
机构
[1] Univ Calif San Francisco, UCSF Cell Design Inst, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Diabet Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA
[5] Univ Calif San Francisco, UCSF CoLabs, San Francisco, CA USA
[6] Univ Calif San Francisco, Parker Inst Canc Immunotherapy, San Francisco, CA USA
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94118 USA
[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[9] Univ Hosp Rechts Isar MRI, Ctr Organoid Syst, Garching, Germany
[10] Tech Univ Munich, Garching, Germany
[11] Helmholtz Munich, Inst Diabet Organoid Technol, Helmholtz Diabet Ctr, Neuherberg, Germany
[12] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Garching, Germany
[13] German Ctr Diabet Res DZD, Neuherberg, Germany
关键词
IMMUNE CELLS; IMMUNOTHERAPY; RECOGNITION; CHALLENGES; CANCER;
D O I
10.1126/science.adl4793
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Immune homeostasis requires a balance of inflammatory and suppressive activities. To design cells potentially useful for local immune suppression, we engineered conventional CD4+ T cells with synthetic Notch (synNotch) receptors driving antigen-triggered production of anti-inflammatory payloads. Screening a diverse library of suppression programs, we observed the strongest suppression of cytotoxic T cell attack by the production of both anti-inflammatory factors (interleukin-10, transforming growth factor-beta 1, programmed death ligand 1) and sinks for proinflammatory cytokines (interleukin-2 receptor subunit CD25). Engineered cells with bespoke regulatory programs protected tissues from immune attack without systemic suppression. Synthetic suppressor T cells protected transplanted beta cell organoids from cytotoxic T cells. They also protected specific tissues from unwanted chimeric antigen receptor (CAR) T cell cross-reaction. Synthetic suppressor T cells are a customizable platform to potentially treat autoimmune diseases, organ rejection, and CAR T cell toxicities with spatial precision.
引用
收藏
页数:14
相关论文
共 44 条
  • [1] Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
    Roybal, Kole T.
    Williams, Jasper Z.
    Morsut, Leonardo
    Rupp, Levi J.
    Kolinko, Isabel
    Choe, Joseph H.
    Walker, Whitney J.
    McNally, Krista A.
    Lim, Wendell A.
    CELL, 2016, 167 (02) : 419 - +
  • [2] Therapeutic T cells with synthetic gene circuits act locally
    Marchal, Iris
    NATURE BIOTECHNOLOGY, 2025, 43 (01) : 30 - 30
  • [3] Engineering T cells for cancer: our synthetic future
    Vonderheide, Robert H.
    June, Carl H.
    IMMUNOLOGICAL REVIEWS, 2014, 257 (01) : 7 - 13
  • [4] Engineering nanoparticles to locally activate T cells in the tumor microenvironment
    Wang, Dangge
    Wang, Tingting
    Yu, Haijun
    Feng, Bing
    Zhou, Lei
    Zhou, Fangyuan
    Hou, Bo
    Zhang, Hanwu
    Luo, Min
    Li, Yaping
    SCIENCE IMMUNOLOGY, 2019, 4 (37)
  • [5] Genetic engineering of therapeutic T cells using synthetic nanoparticles
    Moffett, Howell F.
    Smith, Tyrel T.
    Stephan, Matthias T.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [6] Engineering T cells to eradicate tumors in the age of synthetic biology
    Greenberg, Philip D.
    Anderson, Kristin G.
    Egan, Dan
    Hingorani, Sunil R.
    Oda, Shannon K.
    Perret, Rachel
    Schmitt, Tom M.
    Stromnes, Ingunn M.
    Schmidt, Leah
    Chapuis, Aude G.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [7] Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
    Esensten, Jonathan H.
    Bluestone, Jeffrey A.
    Lim, Wendell A.
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 12, 2017, 12 : 305 - 330
  • [8] Cytokine-Functionalized Synthetic Dendritic Cells for T Cell Targeted Immunotherapies
    Eggermont, Loek J.
    Hammink, Roel
    Blank, Kerstin G.
    Rowan, Alan E.
    Tel, Jurjen
    Figdor, Carl G.
    ADVANCED THERAPEUTICS, 2018, 1 (06)
  • [9] Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology
    Choe, Joseph H.
    Williams, Jasper Z.
    Lim, Wendell A.
    ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4, 2020, 4 : 121 - 139
  • [10] Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5+CD8+ T Cells
    Zimmerer, Jason M.
    Chaudhari, Sachi
    Koneru, Kavya
    Han, Jing L.
    Abdel-Rasoul, Mahmoud
    Uwase, Hope
    Yi, Tai
    Breuer, Christopher K.
    Bumgardner, Ginny L.
    TRANSPLANTATION DIRECT, 2025, 11 (02):